Pain Therapeutics (PTIE) Earning Somewhat Favorable Media Coverage, Study Shows
Headlines about Pain Therapeutics (NASDAQ:PTIE) have trended somewhat positive recently, according to Accern Sentiment. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pain Therapeutics earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 47.3088131893637 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Shares of Pain Therapeutics (PTIE) opened at 3.25 on Friday. Pain Therapeutics has a 12-month low of $0.51 and a 12-month high of $4.82. The stock has a 50 day moving average price of $3.49 and a 200 day moving average price of $2.40. The stock’s market capitalization is $21.43 million.
Pain Therapeutics (NASDAQ:PTIE) last released its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.64) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.47) by $0.17. On average, equities analysts anticipate that Pain Therapeutics will post $1.51 earnings per share for the current fiscal year.
Several analysts have recently weighed in on PTIE shares. Zacks Investment Research downgraded Pain Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, July 14th. Gabelli downgraded Pain Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, July 17th. Finally, ValuEngine downgraded Pain Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd.
About Pain Therapeutics
Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.
Receive News & Stock Ratings for Pain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics and related stocks with our FREE daily email newsletter.